Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study - Lu, S; Zhou, J; Jian, H (Lancet Respir Med, 2023)